SEGMENT REPORTING (Tables)

3 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

Reconciliation of other significant reconciling items from segments to consolidated

Summarized financial information concerning the Company's reportable segments is shown in the following table (in thousands):

Three Months Ended March 31, 2018	Core Companion Animal Health		Other Vaccines, Pharmaceuticals and Products			Total
Total revenue	$	26,819	$	5,946		$	32,765
Operating income (loss)	1,923		(52		)	1,871
Income (loss) before income taxes	1,927		(52		)	1,875
Capital purchases	57		318			375
Depreciation and amortization	908		288			1,196

Three Months Ended March 31, 2017	Core Companion Animal Health		Other Vaccines, Pharmaceuticals and Products		Total
Total revenue	$	23,784	$	5,775	$	29,559
Operating income	1,146		1,642		2,788
Income before income taxes	1,214		1,636		2,850
Capital purchases	49		431		480
Depreciation and amortization	845		247		1,092

Schedule of revenue from external customers and long-lived assets, by geographical areas

Asset information by reportable segment as of March 31, 2018 is as follows (in thousands):

	Core Companion Animal Health		Other Vaccines, Pharmaceuticals and Products		Total
Total assets	$	117,418	$	20,302	$	137,720
Net assets	80,686		24,404		105,090

Asset information by reportable segment as of December 31, 2017 is as follows (in thousands):

	Core Companion Animal Health		Other Vaccines, Pharmaceuticals and Products		Total
Total assets	$	111,968	$	23,819	$	135,787
Net assets	75,984		24,456		100,440